{
    "nctId": "NCT01658176",
    "briefTitle": "Study Of PF-04691502 (PI3K/mTOR Inhibitor) In Combination With Exemestane Compared With Exemestane Alone In Patients With Advanced Breast Cancer",
    "officialTitle": "An Open-Label Randomized Phase 2 Study Of PF-04691502 (PI3K/mTOR Inhibitor) In Combination With Exemestane Compared With Exemestane Alone In Patients With Estrogen Receptor Positive, Her-2 Negative Advanced Breast Cancer",
    "overallStatus": "WITHDRAWN",
    "conditions": "Breast Neoplasms",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 0,
    "primaryOutcomeMeasure": "Progression-Free Survival",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Inoperable estrogen receptor positive, Her-2 negative advanced breast cancer\n* Previously treated with an aromatase inhibitor\n* Primary or secondary hormone resistance\n* Acceptable glucose control, bone marrow, liver and kidney function\n\nExclusion Criteria:\n\n* Inflammatory breast carcinoma\n* Prior therapy with an agent active on PI3K, Akt, and/or mTOR\n* Known hypersensitivity to exemestane\n* Significant gastrointestinal abnormalities which may impair intake, transit, or absorption of the study drugs\n* Current or anticipated need for food or drugs that are known inhibitors or inducers of CYP3A4",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}